Clinical Trial Update: Meta-Analysis Plan for Pooled Data for Studies VRX-RET-E22-303 and VRX-RET-E22-304

View source ↗

Summary

A meta-analysis plan to pool data from two completed epilepsy studies (VRX-RET-E22-303 and VRX-RET-E22-304) is described by GlaxoSmithKline.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Partial Epilepsy

Drugs mentioned

• VRX-RET investigational epilepsy drug

Snippet

Sponsor: GlaxoSmithKline | Conditions: Epilepsy, Partial | Status: COMPLETED